PMID- 28339294
OWN - NLM
STAT- MEDLINE
DCOM- 20170421
LR  - 20191210
IS  - 1746-0921 (Electronic)
IS  - 1746-0913 (Linking)
VI  - 12
DP  - 2017 Apr
TI  - Rapid assessment of antimicrobial resistance prevalence using a Lot Quality 
      Assurance sampling approach.
PG  - 369-377
LID - 10.2217/fmb-2016-0170 [doi]
AB  - AIM: Increasing antimicrobial resistance (AMR) requires rapid surveillance tools, 
      such as Lot Quality Assurance Sampling (LQAS). MATERIALS & METHODS: LQAS 
      classifies AMR as high or low based on set parameters. We compared 
      classifications with the underlying true AMR prevalence using data on 1335 
      Escherichia coli isolates from surveys of community-acquired urinary tract 
      infection in women, by assessing operating curves, sensitivity and specificity. 
      RESULTS: Sensitivity and specificity of any set of LQAS parameters was above 99% 
      and between 79 and 90%, respectively. Operating curves showed high concordance of 
      the LQAS classification with true AMR prevalence estimates. CONCLUSION: 
      LQAS-based AMR surveillance is a feasible approach that provides timely and 
      locally relevant estimates, and the necessary information to formulate and 
      evaluate guidelines for empirical treatment.
FAU - van Leth, Frank
AU  - van Leth F
AD  - Department of Global Health, Academic Medical Center, University of Amsterdam, 
      Amsterdam Institute for Global Health & Development, Amsterdam, The Netherlands.
FAU - den Heijer, Casper
AU  - den Heijer C
AD  - Department of Medical Microbiology, Maastricht University, School of Public 
      Health & Primary Care, Maastricht, The Netherlands.
AD  - Department of Sexual Health, Infectious Diseases & Environmental Health, Public 
      Health Service South Limburg, Geleen, The Netherlands.
FAU - Beerepoot, Marielle
AU  - Beerepoot M
AD  - Department of Internal Medicine, Division of Infectious Diseases, Academic 
      Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Stobberingh, Ellen
AU  - Stobberingh E
AD  - Department of Medical Microbiology, Maastricht University, School of Public 
      Health & Primary Care, Maastricht, The Netherlands.
FAU - Geerlings, Suzanne
AU  - Geerlings S
AD  - Department of Internal Medicine, Division of Infectious Diseases, Academic 
      Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Schultsz, Constance
AU  - Schultsz C
AD  - Department of Global Health, Academic Medical Center, University of Amsterdam, 
      Amsterdam Institute for Global Health & Development, Amsterdam, The Netherlands.
AD  - Department of Medical Microbiology, Academic Medical Center, University of 
      Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20170324
PL  - England
TA  - Future Microbiol
JT  - Future microbiology
JID - 101278120
RN  - 0 (Anti-Infective Agents)
SB  - IM
MH  - Anti-Infective Agents/*pharmacology/therapeutic use
MH  - *Drug Resistance, Bacterial
MH  - Epidemiologic Methods
MH  - Escherichia coli/*drug effects/isolation & purification
MH  - Escherichia coli Infections/drug therapy/epidemiology/microbiology
MH  - Female
MH  - Humans
MH  - Lot Quality Assurance Sampling
MH  - Prevalence
MH  - Sensitivity and Specificity
MH  - Urinary Tract Infections/drug therapy/epidemiology/microbiology
OTO - NOTNLM
OT  - Lot Quality Assurance Sampling
OT  - antimicrobial resistance
OT  - empirical treatment
OT  - urinary tract infection
EDAT- 2017/03/25 06:00
MHDA- 2017/04/22 06:00
CRDT- 2017/03/25 06:00
PHST- 2017/03/25 06:00 [pubmed]
PHST- 2017/04/22 06:00 [medline]
PHST- 2017/03/25 06:00 [entrez]
AID - 10.2217/fmb-2016-0170 [doi]
PST - ppublish
SO  - Future Microbiol. 2017 Apr;12:369-377. doi: 10.2217/fmb-2016-0170. Epub 2017 Mar 
      24.